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Reversing glomerular hypertension stabilizes established glomerular
injury. Munich—Wistar rats were studied 18 weeks following 5/6 renal
ablation. In untreated group I rats maintained on standard chow
containing 24% protein, sustained systemic and glomerular hyperten-
sion were associated with increasing proteinuria and widespread
glomerular injury. In group 2, early treatment with the converting
enzyme inhibitor enalapril prevented systemic and glomerular hyper-
tension, and largely limited proteinuria and glomerular injury. Groups 3
and 4 received no therapy during the first eight weeks, during which
they developed systemic hypertension and levels of proteinuria previ-
ously shown to be associated with significant glomerular sclerosis at
this time point. Enalapril therapy begun at eight weeks in group 3 rats
reversed systemic and glomerular hypertension, prevented a further
rise in proteinuria, and limited glomerular lesions at 18 weeks relative to
group I. Reduction of dietary protein content to 12% at eight weeks in
group 4 rats controlled glomerular but not systemic hypertension to
near—normal levels, stabilized proteinuria values, and also limited
glomerular lesions at IS weeks compared to group I. These studies
support the view that glomerular hypertension is an essential hemody-
namic derangement responsible for progressive glomeritlar injury.
Furthermore, reduction of capillary pressure can arrest the progression
of remnant glomerular injury even when therapy is delayed until
glomerular injury is established.
Extensive ablation of renal tissue in the rat results in increas-
ing proteinuria and progresive sclerosis of remnant glomeruli.
Recent studies have therefore employed the rat renal ablation
model to identify factors potentially responsible for the progres-
sion of human renal insufficiency [1—6]. One line of evidence
suggests that remnant glomerular injury is initiated by increases
in local capillary pressure and flow which serve to elevate
remnant nephron glomerular filtration rate (GFR). Institution of
dietary protein restriction prior to 11/12 renal ablation has been
shown to blunt subsequent increases in glomerular capillary
pressure and flow and to prevent the development of early
glomerular lesions seen in ablated rats maintained on standard
chow [4]. More recently, use of an angiotensin I converting—
enzyme inhibitor to prevent development of systemic and
glomerular capillary hypertension following reduction in neph-
ron number was shown to limit development of glomerular
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injury in rats subjected to 5/6 renal ablation [6]. These studies
suggest that maneuvers which reduce glomerular capillary
pressure and/or flow could limit the development of glomerular
injury. In particular, the beneficial effects of reducing dietary
protein content in the course of human 171 and experimental [8]
renal disease may reflect the influence of this dietary maneuver
on glomerular hemodynamic function. Previous studies in the
remnant kidney model, however, assess the hemodynamic and
therapeutic effect of protein restriction and antihypertensive
therapy begun at the time of, or prior to, renal ablation. The
present study examines the effects of two therapeutic interven-
tions in remnant kidney rats with already—evident glomerular
injury. Dietary protein restriction or antihypertensive therapy
began eight weeks following 5/6 renal ablation, a time interval at
which previous studies have demonstrated significant glomeru-
lar sclerosis in this model [6]. We sought to show whether these
maneuvers could reduce glomerular capillary pressure and/or
flow after remnant nephron hyperfiltration was established and
whether their effects on glornerular hemodynamic function
would be associated with a reduction in the pace of glomerular
injury.
Methods
Studies were carried out for a period of 18 weeks following
ablation of 5/6 of the renal mass in four groups of male
Munich—Wistar rats. Renal ablation was accomplished by re-
moval of the right kidney and infarction of approximately 2/3 of
the left kidney by ligation of two or three branchs of the left
renal artery in rats with initial body weights of 225 to 245 g.
Group 1 (N = 11) received no specific therapy and was
maintained throughout the entire 18 week experimental period
on standard rat chow containing approximately 24% protein by
weight (Wayne Rodent Blox, Allied Mills, Chicago, Illinois,
USA). Group 2 (N = 10) and group 3 (N = 12) were treated
with the angiotensin I converting—enzyme inhibitor, enalapril
(Merck, Sharp & Dohme, West Point, Pennsylvania, USA).
Group 2 received enalapril in the drinking water at a dose of 50
mg/liter beginning one week after ablation, a regimen which had
previously been shown to prevent development of hypertension
and glomerular injury over a period of eight weeks following
ablation [6]. In group 3, initiation of enalapril treatment was
delayed until eight weeks after ablation when systemic hyper-
tension and proteinuria were established. Enalapril, 50 mg/liter
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in the drinking water, was then administered over the remaining
10 weeks of the study. Like untreated rats in group 1, rats in
both the early and late enalapril treatment groups were main-
tained on standard rat chow throughout the study.
Rats in group 4 received no antihypertensive therapy but
were subjected to dietary protein restriction beginning eight
weeks after ablation, at which time they were switched from the
standard (24% protein) chow to a synthetic diet containing
11.7% protein (TD84206, Teklad Test Diets, Madison, Wiscon-
sin, USA). Because of the relatively low methionine content of
casein, added methionine (0.3%) was incorporated in the syn-
thetic diet. The synthetic diet was further carefully formulated
so that its content of sodium (0.39%), potassium (0.96%),
calcium (1.2%), and phosphorus (0.99%) was matched to that of
the standard chow while carbohydrate content was increased to
provide equal caloric content. Food was provided ad libitum to
all rats, since preliminary studies demonstrated comparable
rates of weight gain among the various groups.
Systolic blood pressure was measured biweekly in each rat
by the tail cuff method [9]. Twenty—four—hour urinary protein
excretion was measured at intervals of 3, 6, 8, Il, 15, and 18
weeks after ablation. Rats were assigned to groups 1, 3, and 4 so
that these groups had comparable levels of proteinuria at the
eight week time point, prior to institution of therapy in groups
3 and 4.
Micropuncture studies
Eighteen weeks after ablation, eight to nine rats from each
group underwent micropuncture study. They were anesthetized
with mactin (100 mg/kg body weight intraperitoneally), and
placed on a temperature—regulated micropuncture table. Imme-
diately after the induction of anesthesia, the left femoral artery
was catheterized with PE-50 polyethylene tubing, followed by a
baseline collection of 210 pi of arterial blood. This arterial
catheter was used for subsequent periodic blood sampling and
estimation of mean arterial pressure (AP). AP was monitored
with an electronic transducer (Model P23Db, Statham Instru-
ments Div., Gould Inc., Oxnard, California, USA) connected to
a direct writing recorder (Model 7702B, Hewlett—Packard Co.,
Palo Alto, California, USA). After tracheostomy, polyethylene
catheters were also inserted into the left and right jugular veins
for infusions of inulin and plasma. Intravenous infusions of
isoncotic rat plasma and 7% inulin solution in 0.9% NaCI were
started at rates of 6.0 and 1.2 ml/hr, respectively. The left
kidney was then exposed by a subcostal incision and separated
from the adrenal gland and the surrounding perirenal fat. The
left ureter was catheterized with PE-lO tubing. The kidney was
then suspended on a Lucite holder, and its surface illuminated
with a fiber—optic light source and bathed with isotonic NaCl.
Since the plasma volume of rats prepared for micropuncture
is reduced by approximately 20% [10], the following protocol
for maintaining the euvolemic state was employed. After inser-
tion of the jugular catheters, isoncotic rat plasma was infused
over approximately 30 minutes, in a total amount equal to 1% of
body weight, followed by a reduction in infusion rate to 0.41
mi/hr for the remainder of each experiment.
Micropuncture measurements were carried out as follows.
Exactly timed (I to 1.5 minute) samples of tubule fluid were
collected from surface proximal convolutions of four to five
nephrons for determination of flow rate and inulin concentra-
tion, and calculation of SNGFR. Three to six samples of
efferent arteriolar blood were obtained for determination of
protein concentration. Coincident with these sample collec-
tions, 140 .d of femoral arterial blood were obtained in each
period for determination of Hct and plasma concentrations of
protein and inulin, and 15 to 30 minute urine collections were
obtained for determination of flow rate and inulin concentra-
tion. Time—averaged hydraulic pressures were measured in
surface glomerular capillaries, proximal tubules, and efferent
arterioles with a continuous recording, servo-null micropipette
transducer system (Model 3, Instrumentation for Physiology
and Medicine, San Diego, California, USA). Hydraulic output
from the servo system was coupled electronically to a second
channel of the Hewlett—Packard recorder by means of a pres-
sure transducer. Colloid osmotic pressure of plasma entering
and leaving glomerular capillaries was estimated from values
for protein concentration in femoral arterial and surface efferent
arteriolar plasma samples, by using the equation derived by
Deen et al [II]. Values for protein concentration, and thus
colloid osmotic pressure, for femoral arterial plasma are taken
as representative of values for these parameters for the afferent
end of the glomerular capillary network. These estimates of
preglomerular and postgiomeruiar plasma protein concentration
and oncotic pressure permit calculation of single nephron
filtration fraction, glomerular capillary ultrafiltration coefficient
(Kf), glomerular capillary plasma flow rate (QA), glomerular and
postglomerular blood flow rates, and single afferent and efferent
arteriolar resistances, using equations described previously
[11].
Morphology
At 18 weeks after ablation, kidneys were fixed by perfusion at
the measured arterial pressure with 1.25% glutaraldehyde in 0.1
M cacodylate buffer (pH 7.4). Following perfusion—fixation, one
or two 3 to 4 mm thick coronal sections through the mid-portion
of the remnant were postfixed in 4 g/100 ml buffered formalde-
hyde solution and processed for light microscopy through
paraffin embedding. Sections 3 im in thickness were stained
with hematoxylin/eosin and by the periodic—acid Schiff tech-
nique. The frequency of focal and segmental glomerular lesions
was determined by examining all glomerular profiles (range, 100
to 150 profiles per animal) contained in one coronal section from
each animal. Segmental sclerotic lesions were defined as areas
of the tuft showing collapse of the glomerular capillaries accom-
panied by hyaline deposition and/or adhesion of the tuft to
Bowman's capsule. For each animal, the number of glomeruli
with segmental sclerotic lesions was expressed as a percentage
of the total number of glomeruli counted.
Analytical
The volume of fluid collected from individual proximal tu-
bules was estaimated from the length of the fluid column in a
constant bore capillary tube of known internal diameter. The
concentration of inulin in tubule fluid was measured, usually in
duplicate, by the microfluorescence method of Vurek and
Pegram [12]. Inulin concentrations in plasma and urine were
determined by the macro-anthrone method of Führ, Kaczmar-
czyk and Kruttgen [13]. Protein concentrations in efferent
arteriolar and femoral arterial blood plasmas were determined,
usually in duplicate, using a fluorometric method of Viets et al
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[14]. Plasma urea nitrogen concentration was measured using a
Beckman Analyzer 2 (Beckman Instruments, Fullerton, Cali-
fornia, USA). Urinary protein concentration was measured by
precipitation with 3% sulfosalicylic acid [15].
Statistical information
The statistical significance of differences among values of
individual parameters in the four experimental groups was
evaluated by the analysis of variance. The Newman—Keuls
multiple range test was used to assess the significance between
individual group means (6 comparisons) with significance de-
fined as P < 0.05. Protein excretion rates, because of their
skewed distribution, were converted to natural logarithm values
for this analysis. Comparison of blood pressures and protein
excretion rates at different time points was made by the paired
t-test. Results are expressed as mean I SEM throughout.
Results
Systemic blood pressure
Results of biweekly systolic blood pressure measurements in
awake rats are depicted in Figure 1. In untreatd group 1 rats,
removal of 5/6 of the renal mass resulted in the development of
systemic hypertension within two weeks after ablation. Blood
pressure in these rats continued to rise over the course of the
experiment so that the mean of the combined 14 and 16 week
values, 177 7 (sEM) mm Hg, was significantly higher than the
mean of the six and eight week values, 165 8 mm Hg (P <
0.05). Comparable hypertension was observed over the first
eight weeks in groups 3 and 4. Institution of enalapril therapy
after this interval promptly lowered systolic blood pressure to
normal levels in group 3 rats and maintained it stable at a value
averaging 133 9 mm Hg over the remaining weeks of the
study. In contrast, reduction of dietary protein intake in group
4 rats had no significant effect on blood pressure, The mean
systolic pressure in these rats remained comparable to that
observed in untreated group I rats. As in previous studies [6],
the development of systemic hypertension was prevented in
group 2 rats in which enalapril therapy was begun shortly after
renal ablation. Average systolic blood pressure values in these
rats from 10 to 16 weeks after ablation were slightly but not
significantly lower than those in group 3 rats which were treated
with enalapril only after hypertension was established.
Micropuncture studies
Mean values for body weight, Hct, plasma urea nitrogen
concentration (PUN), mean arterial pressure under anesthesia
(AP), SNGFR, and the pressures, flows, and resistances gov-
erning glomerular ultrafiltration for the four groups of rats are
summarized in Table I. Body weights were equivalent among
the different groups. Hematocrit was equivalent among the
control and enalapril treated rats, but was slightly reduced in
rats maintained on low protein chow. Values for AP paralleled
values of systolic blood pressure obtained in awake rats.
Untreated group I animals showed marked hypertension with
AP averaging 150 9 mm Hg. Blood pressure was reduced to
normal levels by both early and late institution of enalapril
therapy, but was not significantly affected by dietary protein
restriction. The average PUN level in group 4 was significantly
0 2 4 6 8 10 12 14 16
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Fig. 1. Systolic blood pressure (SBP) measured by the tail cuff method
in conscious rats followed over 16 weeks after 5/6 nephrectomy.
Untreated rats (group I, I) exhibited sustained systemic hypertension
throughout this period. Early administration of enalapril (group 2, A)
prevented the development of systemic hypertension. Rats in groups 3
(0) and 4 (A) were hypertensive during the first 8 weeks; thereafter,
enalapril therapy (group 3) but not protein restriction (group 4) normal-
ized systolic blood pressure. ap < 0.05 SBP reduced vs. group I at same
time point; bp < 0.05 SBP reduced vs. group 3 at same time point.
reduced by protein restriction while groups 1, 2, and 3 main-
tained on standard chow showed comparable azotemia.
Despite the differences in treatment, equivalent single neph-
ron hyperfiltration was observed in the four groups, with
SNGFR values averaging 129 8 nI/mm in group 1, 119 8
nI/mm in group 2, 124 10 nI/mm in group 3, and 127 8 nI/mm
in group 4. In accord with previous studies [4, 6], remnant
nephron hyperfiltration in untreated rats with renal ablation
resulted from elevation of the glomerular capillary flow rate,
QA, and mean hydraulic pressure, GC• Thus, in group 1 QA
averaged 452 32 nllmin, a value more than twice that
observed in intact rats under euvolemic conditions, while the
mean glomerular transcapillary hydraulic pressure difference,
P, averaged 55 3 mm Hg, a value more than 15mm Hg
higher than seen in normal_rats [16]. Elevation of iP was a
consequence of elevation of PGC, which averaged 71 3 mm Hg
in remnant glomeruli. Values for proximal tubule (PT) and
efferent arteriolar hydraulic pressure (PE) were only slightly
higher than previously reported in normal rats [16], and were
not different among the four groups.
Neither antihypertensive therapy with enalapril nor late
institution of dietary protein restriction reduced remnant neph-
ron hyperfiltration. Both maneuvers, however, markedly al-
tered the microvascular hemodynamic determinants responsi-
ble for the elevation of remnant nephron GFR. Reduction of
systemic blood pressure in enalapril treated rats was associated
with reduction of PGC so that the average values of P in group
2 (38 1 mm Hg) and in group 3 (39 1 mm Hg) were reduced
near to the levels seen in normal rats [16]. However, despite the
marked reduction of systemic blood pressure by enalapril
treatment, values for QA in group 2 (402 33 nI/mm) and in
group 3 (440 36 nI/mm) remained equivalent to the value of
452 32 nI/mm observed in untreated group 1 rats. Mainte-
nance of glomerular plasma flow despite reduction of renal
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Table 1. Summary of renal cortical microcirculation studies
Body wt Hct PUN XP GFR SNGFR QA PGC PT
g vol/100,nl ing//OOinI ,n,n i-i g mi/mm n//mum SN FF niI,nin 'am Hg
Group I 335 6 44 I 60 4 ISO 9 0.85 0.ll 129 8 0.29 0.02 452 32 71 3 16 I
(N = 9)
Group 2 340 8 43 I 51 3 99 3" 1.13 0.09 119 8 0.30 0.01 402 33 53 I IS I(N = 9)
Group 3 327 7 44 I 56 4 112 3" lOt 0.12 124 10 0.26 0.02 440 36 54 I' IS I(N = 9)
Group 4 351 8 40 1.d 27 3""" 145 5"" 0.90 0.09 127 8 0.30 0.0! 425 29 56 I" 16 I(N = 8)
Mean values SEM.
—
Abbreviations are: Hct, hematocrit: PUN, plasma urea nitrogen concentration; AP. mean arterial pressure: GFR. glomerular filtration rate;
SNGFR, single nephron glomerular filtration rate: SNFF. single nephron filtration fraction: QA. glomerular plasma flow rate; P. mean
glomerular capillary hydraulic pressure; PT. proximal tubule hydraulic pressure: PF. efferent arteriolar hydraulic pressure; P. mean glomerular
transcapillary hydraulic pressure difference; CA and C1, afferent and efferent arteriolar plasma protein concentration: 7TA and ITF, afferent and
efferent arteriolar colloid osmotic pressure: RA and RE, afferent and efferent arteriolar resistance: RT, total arteriolar resistance (RA + RE); K1,
glomerular capillary ultrafiltration coefficient.
a Values for groups 2. 3, or 4 significantly different from group I. P < 0.05.
b Group 3 different from group 2, P < 0.05.
Group 4 different from group 2. P < 0.05.
"Group 4 different from group 3, P < 0.05.
Table 1. Continued
PE P CA CE A ir1 RA X o0 R1 x lO" RT x b'0
R1JR
K
n//(s mm Hg)m,n Hg g/100 ml mnmn Hg dyne s cm
20
17
17
18
I 55 3
I 38 I'
1 39 I"
I 4t 3
5.5
5.5
5.5
5.2
0.2 7.8
0.2 7.8
0.2 7.5
0.2 7.4
0.2
0.2
0.2
0.2
18 I 31 I 0.84
18 1 31 2 0.55
18 I 29 2 0.63
16 I 29 I 1.04
0.13
0.04
0.08
0.l0'"
0.63
0.51
0.47
0.54
0.07
0.05
0.07
0.03
1.48 0.19
1.06 0.08
1.10 0.15
1.59 0.14
0.44
0.48
0.43
0.35
0.02
0.02
0.02
0.02"'"'
0.077 0.013
0.154 0.017"
0.134 0.023
0.122 0.017
perfusion pressure reflected reductions in total arteriolar resist-
ance, RT. Maintenance of single nephron hyperfiltration despite
reduction of blood pressure was due primarily to maintenance
of an elevated QA and also to an increment in the ultrafiltration
coefficient, K. Filtration pressure disequilibrium was observed
in all group I rats so that unique values for Kf were calculable.
Likewise, unique values for Kf could be calculated for all but
one of the enalapril treated rats; a minimum value of Kf was
calculated for this animal. The average Kf in group 2 rats (0.154
0.017 nl/(sec. mm Hg)) was significantly greater and the
average K [(0.134 0.023 nl/(sec mm Hg)] in group 3 rats was
numerically greater [0.10 > P > 0.05] than the average Kf in
group 1 rats (0.077 0.013 nl/[sec mm Hg]). Values for
afferent and efferent arteriolar protein concentration and colloid
oncotic pressure did not differ among the untreated and
enalapril treated rats. Whole remnant kidney GFR values, like
SNGFR values, did not differ significantly among any of the
groups.
In contrast to enalapril treatment, dietary protein restriction
lowered PGC but not systemic blood pressure in remnant kidney
rats with established hypertension. The average value for PGC
in group 4, 56 1 mm Hg, was comparable to that observed
with enalapril, while the value for RT, 1.59 0.14 X lO!
dynes sec cm5, remained very close to the value of 1.48
0.19 x 10'° dynes sec cm5 observed in group 1 rats. With
values for systemic blood presure and total arteriolar resistance
comparable to those observed in untreated rats, QA remained
elevated at a level of 425 29 nI/rn in despite the reduction of
dietary protein content beginning eight weeks after renal abla-
tion. As in the enalapril treated rats, elevation of QA was
primarily responsible for remnant nephron hyperfiltration. An
apparent increase in K which further contributed to mainte-
nance of hyperfiltration did not achieve statistical significance
(0.10 > P > 0.05 when compared with untreated rats.) Small
reductions in afferent arteriolar protein—concentration and
oncotic pressure associated with chronic dietary protein—
restriction were also not statistically significant.
Proteinuria
Untreated rats with glomerular hypertension developed pro-
gressive glomerular injury as manifested by increasing protein-
uria (Fig. 2). Protein excretion in group 1 rats averaged 49 6
mg/day at eight weeks after ablation, a value comparable to that
observed previously at the same interval in rats subjected to
equivalent renal ablation [6], and increased to an average of 126
13 mg/day at 18 weeks after ablation. In marked contrast,
early institution of enalapril treatment to control glomerular
hypertension restricted proteinuria to low levels in group 2 rats.
In this group, the average protein excretion rate reached a value
of only 29 5 mg/day at 18 weeks after ablation despite
comparable reduction in renal mass. Rats in groups 3 and 4,
which received no treatment during the first eight weeks fol-
lowing ablation, developed proteinuria comparable to that seen
in group I over this period. Reduction of GC after eight weeks
by both enalapril treatment in group 3 and by dietary protein
restriction in group 4 resulted in slight reductions in urine
protein excretion rates at 11 weeks and prevented any further
increase in protein excretion over the remainder of the experi-
756 Meyer ci a!
3 6 9 12 15 18
Time, weeks after ablation
Fig. 2. Twenty—four—hour urinary protein excretion (UPROTV) in rats
with 5/6 nephrectomy. Untreated rats (group I, •) developed progres-
sive proteinuria over the 18 week experimental period. In group 2 (A),
early administration of enalapril markedly limited the development of
proteinuria. UPROTV values in groups 3 (0) and 4 () rose to levels
comparable to those seen in group I rats during the first 8 weeks, but
enalapril therapy (group 3) and protein restriction (group 4) both
prevented any further rise in proteinuria thereafter. ap < 0.05 vs. group
1 at same time point; bJ) < 0.05 vs. group 3 at same time point; CP <0.05
vs. group 4 at same time point.
ment. Average protein excretion rates at 18 weeks in group 3
(49 9 mg/day) and group 4 (39 4 mg/day) were similar and
were both significantly lower than the protein excretion rate in
group I at this interval.
Glomerular structure
Examination of perfusion—fixed kidney tissue showed that
proteinuria reflected development of glomerular injury (Fig. 3).
In untreated group 1 rats, sustained glomerular capillary hyper-
tension was associated with heavy proteinuria and segmental
sclerosis in 34.0 4.4% of glomeruli at 18 weeks after ablation.
Initiation of enalapril treatment to control systemic and glomer-
ular hypertension after proteinuria was established limited the
progression of glomerular injury in group 3 rats. The mean
prevalence of segmental glomerular sclerotic—lesions in this
group, 12.6 2.8%, was markedly lower than that in group I (P
< 0.01). Similarly, restriction of dietary protein intake which
reduced PGC but not systemic pressure limited the progression
of glomerular injury in group 4 rats. The mean prevalence of
segmental sclerotic lesions in this group, 14.9 2.2%, was
close to the value observed in group 3 and again markedly lower
than the value observed in group 1 (P < 0.01). In group 2 rats,
prevention of glomerular capillary hypertension throughout the
entire period following renal ablation limited development of
sclerotic lesions to only 1.6 0.5% of glomeruli, a value
significantly lower than those observed in any of the other
groups.
Discussion
Fifty years ago Chanutin and Ferris [17] and their collabora-
tors [18] showed that the removal of 5/6 of the renal mass in rats
resulted in a syndrome of hypertension and proteinuria associ-
ated with progressive sclerosis of remnant glomeruli. More
1 3
Group
Fig. 3. Prevalence of segmental gloinerular sclerosis in rats studied 18
weeks after 5/6 nephrectomy. Untreated group I rats demonstrated
widespread glomerular injury. Glomerular injury was largely prevented
in group 2 rats treated with enalapril throughout this period, and
markedly lessened in rats started in enalapril (group 3) or low protein
chow (group 4) 8 weeks after ablation.
recent studies have sought to identify factors responsible for
glomerular injury following ablation of renal tissue [1—61. One
line of evidence suggests that changes in glomerular hemody-
namic function evoked by reduction in nephron number cause
remnant glomerular sclerosis. Early micropuncture studies
demonstrated increases in SNGFR of remnant nephrons follow-
ing renal ablation [19]. Hostetter et al [4] showed that remnant
nephron hyperfiltration in rats subjected to 11/12 renal ablation
resulted from increased plasma flow—rates and transcapillary
hydraulic pressures in remnant glomeruli. They further showed
that restriction of dietary protein intake, instituted one week
before the ablation procedure, blunted these hemodynamic
changes and largely prevented development of early glomerular
lesions seen in rats subjected to renal ablation while maintained
on standard chow. More recently Anderson et al [6] used the
angiotensin I converting enzyme—inhibitor, enalapril, to prevent
development of systemic hypertension in rats subjected to 5/6
renal ablation. Therapy with this agent, begun five to ten days
after ablation, prevented elevation of glomerular capillary as
well as systemic blood pressure and reduced the prevalence of
glomerular lesions seen at eight weeks after ablation.
Taken together, the results of Hostetter et al [4] and
Anderson et al [6] suggest that elevation of glomerular capillary
hydraulic—pressure may be an essential hemodynamic derange-
ment responsible for progressive glomerular injury in the rem-
nant kidney. An initial object of the current study was to
determine the efficacy of lowering capillary hydraulic pressure
in remnant glomeruli over a longer period following renal
ablation. Micropuncture studies in group 1 confirmed that
systemic hypertension in untreated rats was accompanied by
sustained glomerular capillary hypertension over a period of 18
weeks following renal ablation. Indeed the mean value obtained
for £P at 18 weeks in the current study, 55 3 mm Hg, was
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comparable to the value for of 52 2 mm Hg previously
obtained four weeks after ablation in rats studied under similar
conditions [6]. Along with elevation of QA, this elevation of zP in.
creased SNGFR to an average value more than twice normal.
As expected, sustained glomerular hypertension and hyperfil-
tration in untreated rats were associated with progressively
increasing proteinuria and development of widespread glomer-
ular injury. In contrast, both systemic blood pressure and
glomerular capillary pressure remained near normal in group 2
rats treated with enalapril throughout the period following
ablation. As in previous studies, enalapril treatment maintained
total arteriolar resistance at a level lower than that seen in the
remnant kidneys of untreated rats. QA was thus elevated to
levels comparable to those seen in untreated rats despite the
reduction in renal perfusion pressure. Elevation in QA along
with a significant increase in Kf resulted in maintenance of
remnant nephron hyperfiltration despite the reduction in P in
enalapril treated rats. Serial urine protein determinations and
morphologic analysis showed that sustained glomerular
hyperperfusion and hyperfiltration without glomerular capillary
hypertension resulted in remarkably little glomerular injury.
An important further object of the current study was to
determine whether reduction of capillary pressure could retard
the progresion of ongoing glomerular injury. In group 3 rats,
initiation of enalapril therapy was therefore delayed until eight
weeks after ablation. Previous studies demonstrating frequent
segmental glomerular—lesions associated with proteinuria at
eight weeks after ablation in similarly prepared rats provided
the basis for selection of this interval. The same dose of
enalapril which prevented any increase in blood pressure fol-
lowing ablation in group 2 rats proved remarkably effective in
reversing established hypertension in group 3 rats. Over the last
eight weeks of the experiment systolic blood pressures in these
rats were maintained at levels similar to those observed in our
laboratory in intact rats with two kidneys, Micropuncture
studies showed that reduction of systemic blood pressure was
accompanied by reduction of PGC, while morphologic studies
showed that late institution of enalapril therapy markedly
reduced the extent of glomerular injury at 18 weeks. These
results suggest that reduction of local capillary pressure exerts
a beneficial effect on remnant glomeruli even when hyperten-
sion and intitial glomerular injury have become established.
Further evidence for a beneficial effect of reducing GC in the
setting of ongoing glomerular injury was obtained in rats
subjected to dietary prtein restriction. Previous studies have
shown that dietary protein restriction reduces remnant nephron
damage and prevents early mortality in rats subjected to renal
ablation [3, 4, 20, 21]. In each of these studies, dietary protein
restriction was instituted at the time of, or prior to, the ablation
procedure. In addition, these studies have either employed
protein restriction severe enough to impair body growth or have
compared the effects of moderate protein restriction to those of
feeding protein—rich chows. In the current study, dietary pro-
tein content was reduced from 24% to 12% beginning eight
weeks after ablation. Moderate protein restriction allowed body
growth equivalent to that of rats maintained on standard chow.
As in rats started on enalapril at this interval, high protein
excretion rates suggested the presence of established glomeru-
lar injury prior to the initiation of treatment. In the setting of
established glomerular hyperfiltration, dietary protein restric-
tion caused a reduction of glomerular capillary pressure similar
to that seen with enalapril without reducing remnant nephron
GFR. Morphologic studies showed that despite the persistence
of both systemic hypertension and glomerular hyperfiltration,
reduction of PGC was again associated with marked reduction in
the prevalence of glomerular lesions.
The similar reduction in glomerular injury observed with
dietary protein restriction and late enalapril treatment strongly
suggests that both these maneuvers protect the remnant
glomerulus by lowering capillary hydraulic pressure. Of note,
the glomerular hemodynamic alterations which serve to reduce
PGC in protein restricted rats were different from those which
resulted in an equivalent reduction in PGC in rats treated with
enalapril. As in previous studies of rats with reduced renal
mass, protein restriction did not reduce systemic blood pres-
sure [21, 22]. Reduction of PGC was related to a significant
reduction in the proportion of efferent arteriolar resistance to
total arteriolar resistance, RE/RT, while total arteriolar resist-
ance remained nearly unchanged. A surprising feature of the
current study was the continued elevation of QA in protein
restricted rats with remnant kidneys. Elevation of QA, along
with an increase in Kf, resulted in maintenance of remnant
nephron hyperfiltration despite dietary protein restriction. In a
previous study, institution of more stringent dietary protein
restriction prior to renal ablation limited increases in QA and
SNGFR as well as in PGC in remnant nephrons [4]. It is not clear
whether the different effect observed in the current study
reflected a more moderate degree of protein restriction or was
the result of protein restriction instituted after remnant nephron
hyperfiltration was established.
Maintenance of remnant nephron hyperfiltration despite pro-
tein restriction is of particular interest in light of the potential
relevance of studies in the rat renal ablation model to the
regular progression of serious human renal insufficiency [23].
Recent studies have shown that dietary protein restriction
retards further loss of renal function in patients whose kidneys
have been damaged by a number of diseases [7, 24]. Presum-
ably, the benefit afforded by protein restriction may result from
alterations in the hemodynamic function of surviving nephrons
least damaged by the initial disease process. Available measure-
ments, however, suggest that institution of dietary protein
restriction in patients with renal insufficiency is not attended by
a prompt reduction in GFR, such as might have been expected
on the basis of initial renal function measurements in protein—
restricted remnant kidney rats [25—281. The current study
suggests that protein restriction protects the glomerulus by
lowering capillary hydraulic pressure, but that this beneficial
hemodynamic effect may not be reflected by a parallel decline in
GFR when protein restriction is instituted after renal insuffi-
ciency is established.
A further interesting aspect of the current study was the
relation of protein excretion rates to changes in glomerular
capillary hydraulic—pressure. Previous studies have shown that
protein excretion rate reliably predicts the prevalence of
glomerular injury in the remnant kidney [4—6, 20—221. Studies
with tracer macromolecules have shown that proteinuria in this
model results from impairment of both the charge— and
size—selective properties of the glomerular capillary wall [20].
Infusion of angiotensin II, which increases POC, has been
shown to enhance dramatically the passage of large tracer
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macromolecules across the glomerular capillary wall [29]. It
might therefore be expected that reduction of PGC would reduce
protein excretion rates in the_remnant kidney. In the current
study, however, reduction of PGC by dietary protein restriction
and by antihypertensive therapy stabilized but did not markedly
reduce protein excretion rates. This finding suggests that pro-
tein excretion rates may not necessarily reflect the acute effects
of different therapies on glomerular hemodynarnic function in
patients with chronic renal disease, in whom POC cannot be
measured directly. Such extrapolation from rat to human stud-
ies of course requires caution. It is possible, for instance, that
over a longer period than was employed in the current study
reduction of GC would result in actual regression of remnant
glomerular lesions, accompanied by a reduction in protein
excretion rate.
Longer—term studies might establish that sustained elevation
of plasma flow or filtration rate also damage the glomerulus.
The current study suggests, however, that elevation of PGC is
the essential hemodynamic derangement responsible for
glomerular injury following reduction of nephron number. This
result is in accord with the original suggestion of Heptinstall and
Hill [30] and of Azar et al [31] that elevation of PGC causes
glomerular injury in rats with experimental hypertension. Other
recent results which support this hypothesis include the dem-
onstration that only antihypertensive therapy which prevents
glomerular capillary hypertension limits glomerular injury in
rats with renal ablation [32] or with mineralocorticoid—salt
hypertension [33], and the finding that prevention of local
capillary hypertension preserves glomerular structure in rats
with nephrotoxic serum nephntis [34]. The current study estab-
lishes the comparable efficacy of two maneuvers which reduce
PGC, dietary protein restriction and converting enzyme inhibitor
treatment, in the setting of ongoing remnant glomerular injury.
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